Daily administration of erlotinib

2 trials

Sponsors

North East Japan Study Group /The Tokyo Cooperative Oncology Group, Hiroshima citizens hospital Department of Medical Oncology

Conditions

Pre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smoker

Phase 2

Phase II study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR(NEJ006/TCOG0903)

Active, not recruitingJPRN-UMIN000002795

North East Japan Study Group /The Tokyo Cooperative Oncology GroupPre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smoker

Start: 2009-11-01Target: 43Updated: 2026-06-29

Unknown Phase

PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR

Active, not recruitingJPRN-UMIN000005491

Hiroshima citizens hospital Department of Medical OncologyPre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smoker

Start: 2010-01-01Target: 40Updated: 2026-06-29